Brain Biotech Ag · XETR:BNN
Brain Biotech — Investor Day (December 2024)
15 slides from Brain Biotech's investor day presentation, Dec 12, 2024
Slide 1: Growth Initiatives and Margin Drivers
BRAIN Biotech CMD 2024 Daren Bryce, Vice President Food & Pharmaceuticals Growth Initiatives and Margin Drivers Zwingenberg, December 12th, 2024 Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assum
Slide 3: Our Focus Is on High Value Markets in the Food And Life Science Sectors
Our Focus Is on High Value Markets in the Food And Life Science Sectors successful multi-niche solution provider adding value through delivering functionality, flavour & texture Baking Dairy Protein Fruit Juice & Wine improved bread shelf life unique dairy flavours Plant based proteins improved yiel
Slide 4: Our Margins Are Driven by Deep Application Knowledge And Focussing on Emerging Trends
Our Margins Are Driven by Deep Application Knowledge And Focussing on Emerging Trends Sustainability & healthy living are key trends in our markets Sustainability • Increasing yields in fruit juice and wine production • Increased shelf life of baking products • Improved taste & texture in plant-base
Slide 5: Growing Our Enzyme Business And Market Share
Growing Our Enzyme Business And Market Share shared technology, customer satisfaction and customer intimacy are our USP’s CRO CRO CRO CRO We offer a unique combination of business models that enables Shared Technology access our shared technology platform Products Products Products CMO CMO Product
Slide 6: Growing our Enzyme Business And Market Share
Growing our Enzyme Business And Market Share we will organically grow our products business with three main initiatives Geographical expansion by increasing our market penetration of new territories with existing products Developing New Products to grow our sales in existing markets by launching
Slide 7: We Have Direct Routes to Market in Europe And North America
We Have Direct Routes to Market in Europe And North America strong routes to market with a multinational customer base and a distribution network for other territories Distribution Network LATAM MENA Aus/NZ South Africa Niche Markets 6 of the top 10 pharmaceutical 4 of the top 10 food companies 4 of
Slide 8: Combining Resources to Accelerate Growth in New Markets
Combining Resources to Accelerate Growth in New Markets ‘Cross fertilization’ of our existing strengths opens new routes to market Consolidating existing US dairy & food specialties business with our US site to strengthen customer service Investment in US business to expand site and commercial t
Slide 9: Expanding Our Successful Baking Business Model to New Geographical Territories
Expanding Our Successful Baking Business Model to New Geographical Territories combining passionate application know how with excellent customer service Growth in Europe, LATAM, MENA has been 15% CAGR in past three years and is expected to continue Developing US business through direct route to
Slide 10: Growth Accelerated Through Multiple New Product Launches
Growth Accelerated Through Multiple New Product Launches successful product launches and strong product development pipeline Deltabrew® Pure, PlantPro™ and Lipomod® recently launched with 48 customer evaluations underway Launch of new product in egg processing market driving current sales growth
Slide 11: Revenue Growth From New Products in Existing Market Segments
Revenue Growth From New Products in Existing Market Segments Launch of microbial product for enzyme modified mayonnaise production • Rapid Sales Growth - Sales to egg market have doubled in 2024 • Growth in Market Share – Current share estimated to be ~5% • Diversification to Consolidate Position -
Slide 12: New Business Area in Life Science Is a ~€500 Million Potential Market for BRAINBiocatalysts
New Business Area in Life Science Is a ~€500 Million Potential Market for BRAINBiocatalysts combining group capabilities creates added value in a high margin market New brand and business model launched in How are we unique? October 2024 The only enzyme discovery, • Strong technology focus and sma
Slide 13: Growth Through Leveraging Existing Competencies
Growth Through Leveraging Existing Competencies using existing CMO sales channel to expand in pharmaceutical CRO CRO CRO Penetrate market with combined CRO/CMO proposition Shared Utilise existing CMO position & shared technology platform Technology CMO Products CMO CMO Develop enzyme product r
Slide 14: Strong Growth Within Products Business to Support €100 million Target
Strong Growth Within Products Business to Support €100 million Target growth delivered from existing market and growth initiatives €75M product sales CAGR 10% New Markets over 6 years Geographic Expansion New Markets New Products Life Science 2022/23 €42.5M Geographic product sales growth New Produc
Slide 15: Thank you very much for your interest.
Thank you very much for your interest. BRAIN Biotech AG Darmstädter Straße 34−36 64673 Zwingenberg, Germany +49 (0) 6251-9331-0 www.brain-biotech-group.com Biocatalysts Ltd. Unit 1, Cefn Coed, Parc Nantgarw, Cardiff CF15 7QQ, Wales, UK +44 1443 843712 www.biocatalysts.com Your contacts: Daren Bryce,